Universal Brain Announces Publication of Groundbreaking Depression Research Using Multiple Event-Related Potentials 
Senior Market Sales® (SMS) Acquires Centurion Senior Services
Successful Medicare Insurance Agency Expands SMS' Eastern U.S. Distribution OMAHA, Neb., Dec. 10, 2024 /PRNewswire/ -- In a quest to...
Hemogenyx Pharmaceuticals PLC Announces Admission of New Ordinary Shares and New ISIN
Admission of New Ordinary Shares and New ISIN LONDON, UNITED KINGDOM / ACCESSWIRE / December 10, 2024 / Hemogenyx Pharmaceuticals...
The Vital Role of Pulmonary Rehabilitation Programs
KENNESAW, GA / ACCESSWIRE / December 10, 2024 / Pulmonary rehabilitation programs are highly effective for the treatment and rehabilitation...
DEA Continues to Block MMJ Marijuana Drug Development for Neurological Disorder
MMJ Submits FDA Investigational New Drug Application for Cannabis-Derived Drug WASHINGTON, DC / ACCESSWIRE / December 10, 2024 / MMJ...
Tallahassee Plastic Surgery Clinic Launches Nouvo Med Spa – Area’s Newest Destination in Non-Invasive Aesthetic Care
TALLAHASSEE, FL / ACCESSWIRE / December 10, 2024 / Tallahassee Plastic Surgery Clinic has introduced Nouvo Med Spa, an advanced...
Vheda Health Achieves I1 HITRUST Certification
Reinforcing Its Commitment to Security and Client Trust COLUMBIA, MD / ACCESSWIRE / December 10, 2024 / Vheda Health, a...
Dr. Amir Bajoghli and Team Publish New Case Study on Aquagenic Urticaria in BMJ Journals
MCLEAN, VA / ACCESSWIRE / December 10, 2024 / Dr. Amir Bajoghli and his colleagues have recently published an insightful...
Dr. Sindhu Srinivas Joins Ankle & Foot Centers of America
A fellowship-trained ankle and foot surgeon and expert in lower-limb salvage, Srinivas will provide a comprehensive range of podiatric services...
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne
- This is Dermata's first allowed U.S. patent application for DMT310, using its Spongilla technology to topically treat acne --...
MIRA Pharmaceuticals Validates Ketamir-2’s Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End
Strong Safety Profile Validated Across Studies, Setting the Stage for Clinical Trials in Neuropathic Pain MIAMI, FL / ACCESSWIRE /...
Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product
~ Supply Chain Now Fully Secure for PF614-MPAR ~ SAN DIEGO, CA / ACCESSWIRE / December 10, 2024 / Ensysce...
Ignite Biomedical Achieves Key Milestone in Precision Medicine with Successful Analytical Validation of TNF-alpha Inhibitor Treatment Response Predictor
Validation Results Pave the Way for Clinical Studies Focused on Transforming Patient Outcomes inInflammatory BowelDisease FRAMINGHAM, MA / ACCESSWIRE /...
Quantum Biopharma Announces That the Safety Review Committee Recommends Commencing Dosing of Second Cohort in the Phase 1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-MS)
TORONTO, ON / ACCESSWIRE / December 10, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical...
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections
Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals KNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a...
Interactive Strength Inc. (Nasdaq:TRNR) Regains Full Compliance With Nasdaq Continued Listing Standards
AUSTIN, TX / ACCESSWIRE / December 10, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or "the Company"), maker of innovative...
AI/ML Innovations to Acquire Quantum Sciences Ltd
VICTORIA, BC / ACCESSWIRE / December 10, 2024 / AI/ML Innovations Inc. (the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce that...
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
Press Release – No. 12 / 2024 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide...
Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer
Reduction in distant recurrence consistently deepened beyond 3-year Kisqali treatment duration in patients with node-positive (N+) and high-risk node-negative (N0)...
H1 Partners with CTI to Streamline Clinical Trial PI and Site Selection for More Inclusive and Efficient Trials
Leading Contract Research Organization integrates H1’s Trial Landscape platform to optimize global site selection, enhance diversity efforts, and streamline operational...
ACC Medlink Highlights Commitment to Excellence in Patient Care at ACMA Case Management Conference
HUNTINGTON BEACH, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- ACC Medlink, a leading provider of long-distance medical transportation services, proudly...